Premaitha Health Stock Price, News & Analysis (LON:NIPT)

GBX 5.25 -0.50 (-8.70 %)
(As of 12/17/2017 02:49 PM ET)
Previous CloseGBX 5.25
Today's RangeGBX 4.96 - GBX 5.43
52-Week RangeGBX 4.05 - GBX 14.40
Volume563,693 shs
Average Volume1.30 million shs
Market Capitalization£8.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Premaitha Health (LON:NIPT)

Premaitha Health logoPremaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company's product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome), Trisomy 13 (Patau's syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time. The Company operates in the United Kingdom and Rest of the World.

Receive NIPT News and Ratings via Email

Sign-up to receive the latest news and ratings for NIPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Enterprise Software
Sub-IndustryN/A
SectorTechnology
SymbolLON:NIPT
CUSIPN/A
Phone+44-161-6676865

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.03)
Net IncomeN/A
Net Margins-264.31%
Return on Equity-380.42%
Return on Assets-64.92%

Miscellaneous

EmployeesN/A
Outstanding Shares321,220,000

Premaitha Health (LON:NIPT) Frequently Asked Questions

What is Premaitha Health's stock symbol?

Premaitha Health trades on the London Stock Exchange (LON) under the ticker symbol "NIPT."

Where is Premaitha Health's stock going? Where will Premaitha Health's stock price be in 2017?

0 brokers have issued 12-month price objectives for Premaitha Health's stock. Their forecasts range from GBX 18 to GBX 18. On average, they anticipate Premaitha Health's share price to reach GBX 18 in the next year. View Analyst Ratings for Premaitha Health.

Who are some of Premaitha Health's key competitors?

Who are Premaitha Health's key executives?

Premaitha Health's management team includes the folowing people:

  • Barry Kenneth Hextall, Chief Financial Officer, Director (Age 47)
  • William Tzocor Denman IV, Executive Director (Age 52)
  • Adam Reynolds, Non-Executive Chairman of the Board (Age 53)
  • Alan Chang, Director
  • Bill Chang, Director
  • Nicholas Mustoe, Non-Executive Director (Age 52)

How do I buy Premaitha Health stock?

Shares of Premaitha Health and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Premaitha Health's stock price today?

One share of Premaitha Health stock can currently be purchased for approximately GBX 5.25.

How big of a company is Premaitha Health?

Premaitha Health has a market capitalization of £8.78 million.

How can I contact Premaitha Health?

Premaitha Health's mailing address is Rutherford House, 40 Pencroft Way, MANCHESTER, M15 6SZ, United Kingdom. The company can be reached via phone at +44-161-6676865.


MarketBeat Community Rating for Premaitha Health (NIPT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Premaitha Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Premaitha Health (LON:NIPT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 21GBX 21GBX 21GBX 21

Premaitha Health (LON:NIPT) Consensus Price Target History

Price Target History for Premaitha Health (LON:NIPT)

Premaitha Health (LON:NIPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/11/2017FinnCapReiterated RatingCorporateView Rating Details
7/4/2016Panmure GordonReiterated RatingBuyGBX 24View Rating Details
(Data available from 12/17/2015 forward)

Earnings

Earnings History for Premaitha Health (LON:NIPT)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Premaitha Health (LON:NIPT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Premaitha Health (LON:NIPT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Premaitha Health (LON NIPT) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Premaitha Health (LON:NIPT)

Premaitha Health (LON NIPT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Hextall,Barry KennethInsiderBuy180,736GBX 18£32,532.48
(Data available from 1/1/2013 forward)

Headlines

Premaitha Health (LON NIPT) News Headlines

Source:
DateHeadline
Premaitha Expands Middle East Customer Base With Four New LabsPremaitha Expands Middle East Customer Base With Four New Labs
www.morningstar.co.uk - November 28 at 10:21 AM
FinnCap Reaffirms Corporate Rating for Premaitha Health PLC (NIPT)FinnCap Reaffirms Corporate Rating for Premaitha Health PLC (NIPT)
www.americanbankingnews.com - November 27 at 8:26 PM
Is Premaitha Health PLC (AIM:NIPT) A Financially Sound Company?Is Premaitha Health PLC (AIM:NIPT) A Financially Sound Company?
finance.yahoo.com - November 24 at 9:24 AM
FinnCap Reiterates "Corporate" Rating for Premaitha Health PLC (NIPT)FinnCap Reiterates "Corporate" Rating for Premaitha Health PLC (NIPT)
www.americanbankingnews.com - November 23 at 11:20 PM
Further Patent Infringement Claims - London South East (registration) (blog)Further Patent Infringement Claims - London South East (registration) (blog)
www.lse.co.uk - September 8 at 6:24 AM
Before You Buy Premaitha Health PLC’s (AIM:NIPT), You Should Consider ThisBefore You Buy Premaitha Health PLC’s (AIM:NIPT), You Should Consider This
finance.yahoo.com - September 8 at 6:24 AM
Premaitha Health PLC (NIPT) Stock Rating Reaffirmed by FinnCapPremaitha Health PLC (NIPT) Stock Rating Reaffirmed by FinnCap
www.americanbankingnews.com - August 28 at 5:36 PM
Premaitha Launches Prenatal Testing Product Sage In Asia PacificPremaitha Launches Prenatal Testing Product Sage In Asia Pacific
www.morningstar.co.uk - June 16 at 8:11 AM
Premaitha Health Highlights Progress By Yourgene Acquisition In IndiaPremaitha Health Highlights Progress By Yourgene Acquisition In India
www.morningstar.co.uk - June 5 at 8:55 AM
Premaitha establishes first service lab in Asia - London South East (registration) (blog)Premaitha establishes first service lab in Asia - London South East (registration) (blog)
www.lse.co.uk - November 22 at 10:41 AM
Full Year 2016 Premaitha Health PLC Earnings Release - Time Not SuppliedFull Year 2016 Premaitha Health PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 30 at 11:39 AM
Investment agreement extension with Thermo Fisher - London South East (registration) (blog)Investment agreement extension with Thermo Fisher - London South East (registration) (blog)
www.lse.co.uk - September 23 at 5:57 PM
Premaitha propels prenatal test into Indian marketPremaitha propels prenatal test into Indian market
uk.finance.yahoo.com - February 3 at 3:46 AM
Premaitha expands prenatal product into two new marketsPremaitha expands prenatal product into two new markets
uk.finance.yahoo.com - January 27 at 12:05 PM
REPEAT: Premaitha Welcomes Recommendation On NHS Pre-Natal Screening - London South East (registration) (blog)REPEAT: Premaitha Welcomes Recommendation On NHS Pre-Natal Screening - London South East (registration) (blog)
www.lse.co.uk - January 17 at 7:39 PM
Premaitha Health confident about full year after Thermo Fisher dealPremaitha Health confident about full year after Thermo Fisher deal
uk.finance.yahoo.com - December 14 at 11:42 AM
Half Year 2016 Premaitha Health PLC Earnings Release - Time Not SuppliedHalf Year 2016 Premaitha Health PLC Earnings Release - Time Not Supplied
biz.yahoo.com - December 14 at 7:07 AM
Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo Fisher ScientificPremaitha Health PLC Premaitha Health signs Investment Agreement with Thermo Fisher Scientific
uk.finance.yahoo.com - December 14 at 2:17 AM

SEC Filings

Premaitha Health (LON:NIPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Premaitha Health (LON NIPT) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.